2. Stem Cell/Wnt TGF-beta/Smad
  3. TGF-beta/Smad
  4. Luspatercept (mIgG2a)

Luspatercept (mIgG2a)  (Synonyms: RAP-536)

Cat. No.: HY-P99720A Purity: 99.78%
COA
SDS
Technical Support

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects.

For research use only. We do not sell to patients.

CAS No. : 1373715-00-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg Get quote
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Luspatercept (mIgG2a):

Luspatercept (mIgG2a) Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects[1].

Species Reactivity

Human
In Vivo

Luspatercept (mIgG2a) (RAP-536) (1 mg/kg, s.c., twice weekly for 2 months) alleviates anemia by promoting late-stage erythroid differentiation, reduces α-globin aggregates and hemolysis, and mitigates IE and related disease complications in murine β-thalassemia mice model[1].
Luspatercept (mIgG2a) (30 mg/kg, i.p., once for 12 h) inhibits overactivation of Smad2/3 in splenic erythroid precursors in murine β-thalassemia mice model[1].
Luspatercept (mIgG2a) (1-10 mg/kg, s.c., twice weekly for 2 months or once for 72 h) promotes terminal erythroid differentiation in the bone marrow and spleen and increases peripheral red cells in EPO-pretreated wild-type mice [1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old) with hydrogen peroxidenot (50 μM) or not[1].
Dosage: 1 mg/kg
Administration: s.c., twice weekly for 2 months and then collected bone marrow, spleen and liver tissues.
Result: Significantly increased 29% RBC number, 16% hemoglobin concentration, and 19% hematocrit.
Decreased 8% mean cell volume, 10% mean cell hemoglobin, and 2% mean cell hemoglobin concentration.
Reduced 33% reticulocytes and a 19% red cell distribution width area.
Induced an overall increase in the proportion of late-stage erythroid precursors, significantly decreased the cell population of R1 while an increase of R3 in bone marrow, and reduced R1 and R2 with a significant increase in R3 in the spleen.
Reduced ∼60% serum EPO level, 36% splenomegaly, serum concentrations of ferritin (15%) and iron (28%), 29% transferrin saturation.
Reduced iron levels in liver (1464 μg/mg dry weight) and kidney (648 μg/mg dry weight) and altered the iron distribution with restoration of architecture in spleen.
Increased Hamp mRNA levels approximately 2 times without the expression changes of Bmp6 in liver and Gdf15 or Twsg1 in spleen.
Reduced 40% mean concentrations of total bilirubin and occurrence of abnormal erythrocyte morphology and hemolytic debris, but increased mean erythrocyte life span (28 vs 20 days).
Markedly reduced heinz bodies and 38% mean membrane-associated α-globin aggregates in peripheral erythrocytes.
Reduced ROS levels significantly in immature (CD71+Ter119+) and mature (CD71−Ter119+) erythroblasts as well as in peripheral red cells.
Reduced peroxide-stimulated ROS levels and significantly increased 17% bone mineral density, 100% trabecular bone volume (100%), number (14%), and thickness (14%).
Increased cortical thickness with a decrease in marrow space.
Animal Model: Hbbth1/th1 mice of the B6.D2-Hbbd3th/BrkJ strain (3-4 months old)[1].
Dosage: 30 mg/kg
Administration: i.p., once for 12 h, and then collected bone marrow, spleen and liver tissues.
Result: Reduced phosphorylated Smad2/3 level in erythroid precursors of spleens within 12 h.
Inhibited phospho-Smad2 protein expression in erythroid precursors of spleens within 12 h.
Animal Model: C57BL/6 wild-type mice were injected intraperitoneally with EPO (1500 units/kg) or not[1].
Dosage: 1, 10 mg/kg
Administration: s.c., (1 mg/kg) twice weekly for 2 months, (10 mg/kg) once for 72 h, and then collected bone marrow, spleen and liver tissues.
Result: Promoted terminal erythroid differentiation in the bone marrow and spleen and increased peripheral red cells in EPO-pretreated wild-type mice at 10 mg/kg with EPO stimulation in C57BL/6 wild-type mice.
Did not affect iron parameters and Hamp expression in C57BL/6 wild-type mice.
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

75.709 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Luspatercept (mIgG2a)]
Shipping

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • [ACVR2B (activin A receptor type 2B, ActR-IIB, ActRIIB)]2-Mouse IgG2A
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Luspatercept (mIgG2a) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Luspatercept (mIgG2a)1373715-00-4RAP-536RAP536RAP 536TGF-beta/SmadTransforming growth factor betaFusion proteinInhibitorIneffective erythropoiesisIEβ-thalassemiaAnemiaα-globin aggregatesHemolysisinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Luspatercept (mIgG2a)
Cat. No.:
HY-P99720A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.